Understanding and manipulating the NK1–NK2 balance, inhibiting immunosuppressive signaling circuits (e.g., TGF-β, CCL2, CXCR2, c-MET), and combining NK cell–activating strategies with checkpoint inhibitors represent key opportunities to convert cold BC tumors into hot, immune-infiltrated lesions. The gene discussed is CCL2; the disease is breast cancer.